Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 14, 2010Clinical Cancer ResearchOpen Access

A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

TNTorsten O. NielsenUniversity of British Columbia HospitalJoel S. ParkerJoel S. ParkerUniversity of North Carolina at Chapel HillSLSamuel LeungVancouver General Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Nielsen et al. (2010) studied this question.

synapsesocial.com/papers/69d7af6eb1cb92dd1bb8bb2bhttps://doi.org/10.1158/1078-0432.ccr-10-1282
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)2005 · 2,134 citations
  2. 2Discovery and validation of breast cancer subtypes2006 · 130 citations
  3. 3Multigene Classifiers, Prognostic Factors, and Predictors of Breast Cancer Clinical Outcome2009 · 86 citations
  4. 4Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature2008 · 58 citations
  5. 5Development and Clinical Utility of a 21-Gene Recurrence Score Prognostic Assay in Patients with Early Breast Cancer Treated with Tamoxifen2007 · 180 citations